GGrantIndex
Sort

64,565 grants matching drug discovery

Discovery of Natural Product based Drugs and Bioenergetic Materials from CR

$954,100
David H Sherman · University Of Michigan At Ann Arbor · U01 · FY2010 · TW

Therapeutic use of small-molecule HGF-mimetic for emphysema

$954,039
Bert J. W. M. Oehlen · Angion Biomedica Corporation · R44 · FY2010 · HL

Project 1 UIC Targeting Protein Degradation ClpC1 ATPase

$953,949
Scott G. Franzblau · Global Alliance For Tb Drug Development · U19 · FY2021 · AI

AdaptiSPECT-C: A Next-Generation, Adaptive Brain-Imaging SPECT System for Drug Discovery and Clinical Imaging

$953,794
Michael A King · Univ Of Massachusetts Med Sch Worcester · R01 · FY2021 · EB

Discovery of new cellular targets for small-molecule inhibition of enveloped vir

$953,766
Sean P. J. Whelan · Harvard Medical School · U19 · FY2018 · AI

Next-generation 5-nitroimidazoles against giardiasis

$953,513
Lars Eckmann · University Of California, San Diego · U01 · FY2010 · AI

UT Southwestern Center for Translational Medicine (UL1/KL2/TL1

$953,416
Robert Daniel Toto · Ut Southwestern Medical Center · KL2 · FY2015 · TR

Protein Structure, Stability, and Amyloid Formation

$953,343
Ruth Nussinov · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA

Integrated, Individualized, Intelligent Prescribing (I3P)

$953,342
Joshua C. Denny · Vanderbilt University · U01 · FY2015 · HG

Development of Oncomine Professional as a Platform for Biopharmaceutical Research

$953,247
Daniel R Rhodes · Compendia Bioscience, Inc. · R44 · FY2009 · CA

GalNAc-specific measurement of Galactose-deficient IgA1 as a Biomarker for IgA nephropathy

$953,146
Tomasz Szul · Reliant Glycosciences Llc · R44 · FY2025 · DK

DEVELOPMENTAL FUNDS (Core 002)

$953,077
Norman Edward Sharpless · Univ Of North Carolina Chapel Hill · P30 · FY2016 · CA

Validation of Therapeutic Target and Underlying Biology

$953,058
Gregory Scherrer · Univ Of North Carolina Chapel Hill · U19 · FY2024 · NS

Target and antibiotic discovery in Bacillus anthracis

$952,905
Trius Therapeutics, Inc. · R44 · FY2004 · AI

Boron-containing antimalarial drug discovery

$952,800
Steve Baker · Reactive Biosciences Inc · R44 · FY2023 · AI

AMP RA/SLE Leadership Center

$952,770
Paul Joseph Utz · Stanford University · UM2 · FY2015 · AR

Parent Project - Main Theme (MAIN)

$952,700
Mark J Ratain · University Of Chicago · U01 · FY2013 · GM

PDE4D PET Ligand

$952,592
Mark E Gurney · Tetra Discovery Partners, Inc. · R44 · FY2018 · MH

Towards a quantitative understanding of tumor evolution

$952,560
Raul Rabadan · Columbia University Health Sciences · R35 · FY2022 · CA

The Epilepsy Bioinformatics Study for Antiepileptogenic Therapy (EpiBioS4Rx) Project 2: Preclinical Model for Antiepileptogenic Therapy Screening in Post-traumatic Epilepsy

$952,506
Aristea S Galanopoulou · University Of Southern California · U54 · FY2017 · NS

Glycosaminoglycan-Interacting Small Molecule (GISMO) as Alzheimer's Therapeutics

$952,480
Paul Gregor · Gismo Therapeutics, Inc. · R44 · FY2018 · AG

ALZHEIMER AMYLOIDOGENESIS WITH NEW METHODS

$952,090
Brigham And Women'S Hospital · P01 · FY2000 · AG

Assessing the effects of peripheral immune activation on the NVU following TBI using a vascularized and perfused human blood/BBB model

$952,000
Dritan Agalliu · Columbia University Health Sciences · R61 · FY2021 · HL

In vivo Core

$951,755
David R Andes · University Of Wisconsin-Madison · U19 · FY2021 · AI

Center for Genomics and Healthcare Equality

$951,630
Wylie G Burke · University Of Washington · P50 · FY2014 · HG